Ome

TAE Life Sciences Awarded Patent for Borylated Amino Acid Compositions for Boron Neutron Capture Therapy

Retrieved on: 
Tuesday, March 12, 2024
Neutron, Radiation, Patent, Tyrosine, Research, BTS, Cancer, Ome, BNCT, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 /PRNewswire/ -- TAE Life Sciences, a leading innovator in cancer treatment technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted the company's U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT). This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.

Key Points: 
  • US 11,884,688 B2 , for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT).
  • This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.
  • "This patent represents a significant milestone for TAE Life Sciences, validating the innovative work of our research and development teams.
  • With this patent, TAE Life Sciences solidifies its position as a leader in radiation therapy innovation, poised to transform the landscape of cancer treatment.

Rockland Launches Novel Analytical Tools to Assess Drug Delivery: Revolutionizing Oligonucleotide Therapeutic Development

Retrieved on: 
Tuesday, October 17, 2023
Triage, IHC, Drug development, RNA, Cell, DNA-binding protein, ELISA, In situ hybridization, ADMET, Panel, Absorption, Metabolism, ISH, Collection, MOE, Toxicology, PS, ASO, Small RNA, Ome, Tissue, Immunohistochemistry, Messenger, Serum, Vaccine, Fine chemical

LIMERICK, Pa., Oct. 17, 2023 /PRNewswire/ -- Rockland is a leading USA-based life science company, developing analytical tools that assist in the collection of pharmacodynamic, pharmacokinetic, and toxicology data critical for satisfying regulatory requirements for biological drugs, cell and gene therapies, and RNA therapeutic drugs (e.g., ASO, siRNA, mRNA). To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.

Key Points: 
  • To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.
  • Traditionally, ISH-type assays have been the mainstay method of detecting and localizing oligonucleotides in cells and tissues for nucleic acid therapy development.
  • Introducing the ModDetect™ Phosphorothioate (PS) Panel, an immunoassay-based alternative that provides robust detection of oligonucleotide therapeutic drug delivery and analysis, facilitating the collection of ADMET analytical data for regulatory approval.
  • ModDetect ™ is a growing suite of analytical tools generated against different types of nucleic acid chemical modifications.

Bora Pharmaceuticals Selects Mississauga for its North American Headquarters

Retrieved on: 
Wednesday, December 2, 2020
Mississauga, Ome

MISSISSAUGA, ON, Dec. 2, 2020 /PRNewswire/ - Bora Pharmaceuticals, a leading international contract development and manufacturing organization, has selected Mississauga as the location for its first manufacturing facility and corporate headquarters in North America.

Key Points: 
  • MISSISSAUGA, ON, Dec. 2, 2020 /PRNewswire/ - Bora Pharmaceuticals, a leading international contract development and manufacturing organization, has selected Mississauga as the location for its first manufacturing facility and corporate headquarters in North America.
  • "By choosing Mississauga for its flagship North American facility, Bora Pharmaceuticals has reinforced what so many other notable companies already know that the life sciences sector is thriving in our city and it's the perfect location to call home," said Mayor Bonnie Crombie.
  • Establishing the Mississauga site as part of its global manufacturing network is key to Bora Pharmaceuticals' growth strategy.
  • "We are so pleased that Bora Pharmaceuticals' North American operations will be headquartered in Mississauga," said Bonnie Brown, Director of Economic Development.

Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion

Retrieved on: 
Tuesday, October 29, 2019
FDA, Health, Consumer, Children, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Otorhinolaryngology, Audiology, Otitis media, Pediatrics, RTT, Otitis, Ome, Autoinflation

Study C-009 is designed to explore the effect of daily administration of OP0201 in patients with COME, a non-infectious form of otitis media.

Key Points: 
  • Study C-009 is designed to explore the effect of daily administration of OP0201 in patients with COME, a non-infectious form of otitis media.
  • The study will enroll infants and children with three months or longer of bilateral middle ear effusion and hearing loss.
  • The primary endpoints of study C-009 will be the resolution of middle ear effusion and/or restoration of hearing.
  • We are pleased to have alignment with the FDA on our planned Phase 2a chronic otitis media with effusion study, said Dr. Catherine C. Turkel, President of Novus Therapeutics, Inc.